# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001493152-23-010069
**Filing Date:** 2023-3
**Character Count:** 2750
**Document Hash:** 27150632ac177f98cf4a63e9ea72aedb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-010069.hdr.sgml**: 20230428

**ACCESSION NUMBER**: 0001493152-23-010069

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

March 31, 2023

**<u>Via EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

Attn: Tracie Mariner

---

| | |
|:---|:---|
| **Re:** | **CytoMed Therapeutics Limited (the "Company")** |
|  | **Registration Statement on Form F-1** |
|  | **File No. 333-268456** |

---

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "***Act***"), The Benchmark Company, LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the "***Commission***") take appropriate action to cause the above referenced registration statement to become effective on Friday, March 31, 2023, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

*[Signature Page Follows]*

Securities and Exchange Commission, p. 2

March 31, 2023

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| The Benchmark Company, LLC | The Benchmark Company, LLC |
| By: | */s/ John J. Borer III* |
| Name: | John J. Borer III |
| Title: | Senior Managing Director |

---

cc: CHOO Chee Kong, CytoMed Therapeutics Limited <br> Richard A. Friedman, Sheppard, Mullin, Richter & Hampton LLP <br> Richard I Anslow, Ellenoff Grossman & Schole LLP